{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:25:12Z","timestamp":1788024312972,"version":"build-2784847793"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00833-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:03:40Z","timestamp":1773925420000},"page":"467-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1335-3131","authenticated-orcid":false,"given":"Gurjit S.","family":"Kaeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-0443","authenticated-orcid":false,"given":"Pamela F.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-5295","authenticated-orcid":false,"given":"Linda","family":"Grinnell-Merrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"12","key":"833_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/rheumatology\/kei047","volume":"44","author":"J Zochling","year":"2005","unstructured":"Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxf). 2005;44(12):1483\u201391.","journal-title":"Rheumatology (Oxf)"},{"issue":"9","key":"833_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0351-1","volume":"15","author":"G Bakland","year":"2013","unstructured":"Bakland G, Nossent HC. Epidemiology of spondyloarthritis: a review. Curr Rheumatol Rep. 2013;15(9):351.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"833_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr2.11543","volume":"5","author":"M Magrey","year":"2023","unstructured":"Magrey M, Walsh JA, Flierl S, et al. The International Map of Axial Spondyloarthritis Survey: a US patient perspective on diagnosis and burden of disease. ACR Open Rheumatol. 2023;5(5):264\u201376.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"833_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"833_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-023-00351-w","volume":"7","author":"N Wilson","year":"2023","unstructured":"Wilson N, Liu J, Adamjee Q, et al. Exploring the emotional impact of axial spondyloarthritis: a systematic review and thematic synthesis of qualitative studies and a review of social media. BMC Rheumatol. 2023;7(1):26.","journal-title":"BMC Rheumatol"},{"issue":"1","key":"833_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40744-020-00194-8","volume":"7","author":"E Yi","year":"2020","unstructured":"Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review. Rheumatol Ther. 2020;7(1):65\u201387.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"833_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mayocp.2021.08.007","volume":"97","author":"S Schwartzman","year":"2022","unstructured":"Schwartzman S, Ruderman EM. A road map of the axial spondyloarthritis continuum. Mayo Clin Proc. 2022;97(1):134\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"833_CR8","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","volume":"59","author":"R Winchester","year":"2020","unstructured":"Winchester R, FitzGerald O. The many faces of psoriatic arthritis: their genetic determinism. Rheumatology (Oxf). 2020;59(Suppl 1):i4\u20139.","journal-title":"Rheumatology (Oxf)"},{"issue":"3","key":"833_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.101984","volume":"38","author":"F Oliveira Ramos","year":"2024","unstructured":"Oliveira Ramos F, Zinterl C, Fonseca JE. A lifelong journey: long-term perspectives on juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2024;38(3):101984.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"833_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103638","volume":"23","author":"F Proft","year":"2024","unstructured":"Proft F, Duran TI, Ghoreschi K, Pleyer U, Siegmund B, Poddubnyy D. Treatment strategies for spondyloarthritis: implementation of precision medicine\u2014or \u201cone size fits all\u201d concept? Autoimmun Rev. 2024;23(10):103638.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"833_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78(9):1167\u201378.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"833_CR12","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/medicina58111552","volume":"58","author":"M Paroli","year":"2022","unstructured":"Paroli M, Spadea L, Caccavale R, Paroli MP, Nante N. The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment. Medicina (Kaunas). 2022;58(11):1552.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"833_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","volume":"81","author":"HA Blair","year":"2021","unstructured":"Blair HA. Secukinumab: a review in psoriatic arthritis. Drugs. 2021;81(4):483\u201394.","journal-title":"Drugs"},{"key":"833_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211041854","volume":"13","author":"J Braun","year":"2021","unstructured":"Braun J, Kiltz U, B\u00fchring B, Baraliakos X. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. Ther Adv Musculoskelet Dis. 2021;13:1759720X211041854.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"833_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"12","key":"833_CR16","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3899\/jrheum.090412","volume":"36","author":"V Chandran","year":"2009","unstructured":"Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a long-term prospective study. J Rheumatol. 2009;36(12):2744\u201350.","journal-title":"J Rheumatol"},{"issue":"4","key":"833_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"833_CR18","doi-asserted-by":"publisher","first-page":"e002781","DOI":"10.1136\/rmdopen-2022-002781","volume":"9","author":"A De Vicente Delm\u00e1s","year":"2023","unstructured":"De Vicente Delm\u00e1s A, Sanchez-Bilbao L, Calvo-R\u00edo V, et al. Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review. RMD Open. 2023;9(1):e002781.","journal-title":"RMD Open"},{"key":"833_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737256","volume":"8","author":"AYT Chia","year":"2021","unstructured":"Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing psoriatic arthritis with inflammatory bowel disease and\/or uveitis. Front Med (Lausanne). 2021;8:737256.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"833_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A. Axial spondyloarthritis: a review. JAMA. 2025;333(5):408\u201320.","journal-title":"JAMA"},{"issue":"1","key":"833_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter JJ, van Mens LJ, van der Heijde D, Landew\u00e9 R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18(1):196.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"833_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","volume":"67","author":"N Zeboulon","year":"2008","unstructured":"Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"833_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"833_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus. J Rheumatol. 2019;46(2):190\u20137.","journal-title":"J Rheumatol"},{"key":"833_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.884727","volume":"10","author":"F Brunello","year":"2022","unstructured":"Brunello F, Tirelli F, Pegoraro L, et al. New insights on juvenile psoriatic arthritis. Front Pediatr. 2022;10:884727.","journal-title":"Front Pediatr"},{"issue":"1","key":"833_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135.","journal-title":"Pediatr Rheumatol Online J"},{"key":"833_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.180131","volume":"94","author":"D Zisman","year":"2018","unstructured":"Zisman D, Stoll ML, Butbul Aviel Y, Mellins ED. Juvenile psoriatic arthritis: a report from the GRAPPA 2017 annual meeting. J Rheumatol Suppl. 2018;94:11\u20136.","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"833_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001196","volume":"6","author":"M Turk","year":"2020","unstructured":"Turk M, Hayworth J, Nevskaya T, Pope J. The frequency of uveitis in patients with adult versus childhood spondyloarthritis. RMD Open. 2020;6(2):e001196.","journal-title":"RMD Open"},{"issue":"10","key":"833_CR29","first-page":"1647","volume":"10","author":"S Di Gennaro","year":"2023","unstructured":"Di Gennaro S, Di Matteo G, Stornaiuolo G, et al. Advances in the diagnosis and treatment of enthesitis-related arthritis. Children (Basel). 2023;10(10):1647.","journal-title":"Children (Basel)"},{"issue":"5","key":"833_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/rheumatology\/keab678","volume":"61","author":"JW van Straalen","year":"2022","unstructured":"van Straalen JW, Krol RM, Giancane G, et al. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxf). 2022;61(5):2104\u201312.","journal-title":"Rheumatology (Oxf)"},{"issue":"11","key":"833_CR31","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/rheumatology\/ket256","volume":"52","author":"KL Vidqvist","year":"2013","unstructured":"Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology (Oxf). 2013;52(11):1999\u20132003.","journal-title":"Rheumatology (Oxf)"},{"issue":"2","key":"833_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.semarthrit.2017.05.003","volume":"47","author":"A Luque Ramos","year":"2017","unstructured":"Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2017;47(2):269\u201375.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"833_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102760","volume":"20","author":"SS Groen","year":"2021","unstructured":"Groen SS, Sinkeviciute D, Bay-Jensen AC, et al. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev. 2021;20(3):102760.","journal-title":"Autoimmun Rev"},{"issue":"14","key":"833_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"9999","key":"833_CR35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"1","key":"833_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"833_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, et al. Efficacy and safety of subcutaneous secukinumab 150\u00a0mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther. 2019;6(3):393\u2013407.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"833_CR38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"833_CR39","doi-asserted-by":"publisher","first-page":"e002303","DOI":"10.1136\/rmdopen-2022-002303","volume":"8","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, Pournara E, Gossec L, et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303.","journal-title":"RMD Open"},{"issue":"10235","key":"833_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505.","journal-title":"Lancet"},{"issue":"7","key":"833_CR41","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","volume":"61","author":"F Behrens","year":"2022","unstructured":"Behrens F, Sewerin P, de Miguel E, et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. Rheumatology (Oxf). 2022;61(7):2856\u201366.","journal-title":"Rheumatology (Oxf)"},{"issue":"5","key":"833_CR42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/rheumatology\/keab628","volume":"61","author":"MA D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino MA, Schett G, L\u00f3pez-Rdz A, et al. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology (Oxf). 2022;61(5):1867\u201376.","journal-title":"Rheumatology (Oxf)"},{"issue":"2","key":"833_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.42997","volume":"77","author":"A Kivitz","year":"2025","unstructured":"Kivitz A, Sedova L, Churchill M, et al. Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: results from a randomized, placebo-controlled phase 3 study. Arthritis Rheumatol. 2025;77(2):171\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"833_CR44","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"833_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"833_CR46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150\u00a0mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447\u201362.","journal-title":"Rheumatol Ther"},{"issue":"21","key":"833_CR47","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","volume":"133","author":"F Huang","year":"2020","unstructured":"Huang F, Sun F, Wan WG, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III China-centric study, MEASURE 5. Chin Med J (Engl). 2020;133(21):2521\u201331.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"833_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"J Braun","year":"2018","unstructured":"Braun J, Deodhar A, Landew\u00e9 R, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2):e000749.","journal-title":"RMD Open"},{"key":"833_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211051471","volume":"13","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D, Pournara E, Zieli\u0144ska A, et al. Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Ther Adv Musculoskelet Dis. 2021;13:1759720X211051471.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"833_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, \u00d8stergaard M, Gensler LS, et al. Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig. 2020;40(3):269\u201378.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"833_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/art.42993","volume":"77","author":"A Deodhar","year":"2025","unstructured":"Deodhar A, Supronik J, Kivitz A, et al. Efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis: results from a randomized, placebo-controlled, phase 3 study. Arthritis Rheumatol. 2025;77(2):163\u201370.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"833_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/ard-2022-222849","volume":"82","author":"HI Brunner","year":"2023","unstructured":"Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82(1):154\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"833_CR53","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"833_CR54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"833_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001083","volume":"6","author":"E Dures","year":"2020","unstructured":"Dures E, Shepperd S, Mukherjee S, et al. Treat-to-target in PsA: methods and necessity. RMD Open. 2020;6(1):e001083.","journal-title":"RMD Open"},{"issue":"8","key":"833_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"833_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"833_CR58","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"833_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1):272.","journal-title":"Arthritis Res Ther"},{"key":"833_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, van den Reek JMPA, Bruno M, et al. Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13:100266.","journal-title":"Lancet Reg Health Eur"},{"issue":"Suppl 1","key":"833_CR61","first-page":"i103","volume":"60","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Baraliakos X, Deodhar A, et al. Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses. Rheumatology. 2021;60(Suppl 1):i103-4.","journal-title":"Rheumatology"},{"issue":"1","key":"833_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"833_CR63","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876\u201386.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"833_CR64","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"833_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"833_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"833_CR67","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"833_CR68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"833_CR69","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"833_CR70","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/acr.22411","volume":"66","author":"PF Weiss","year":"2014","unstructured":"Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, DeWitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken). 2014;66(12):1775\u201382.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"833_CR71","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"833_CR72","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3899\/jrheum.190507","volume":"47","author":"AM Orbai","year":"2020","unstructured":"Orbai AM, McInnes IB, Coates LC, et al. Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients. J Rheumatol. 2020;47(6):854\u201364.","journal-title":"J Rheumatol"},{"issue":"3","key":"833_CR73","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40744-021-00337-5","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Husni ME, Gladman DD, et al. Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: pooled analysis of four phase 3 studies. Rheumatol Ther. 2021;8(3):1223\u201340.","journal-title":"Rheumatol Ther"},{"key":"833_CR74","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab improves clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations with inadequate response to NSAIDs: week 52 results from the MAXIMISE trial. Ann Rheum Dis. 2020;79(suppl 1):35\u20136. Abstract OP0053.","DOI":"10.1136\/annrheumdis-2020-eular.638"},{"issue":"1","key":"833_CR75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/rheumatology\/kead181","volume":"63","author":"GS Kaeley","year":"2024","unstructured":"Kaeley GS, Schett G, Conaghan PG, et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Rheumatology (Oxf). 2024;63(1):41\u20139.","journal-title":"Rheumatology (Oxf)"},{"issue":"6","key":"833_CR76","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","volume":"82","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, et al. Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Ann Rheum Dis. 2023;82(6):763\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"833_CR77","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40744-020-00269-6","volume":"8","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Van den Bosch F, Machado PM, et al. Achievement of remission endpoints with secukinumab over 3\u00a0years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2021;8(1):273\u201388.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"833_CR78","first-page":"260","volume":"37","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Conaghan PG, Kvien TK, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol. 2019;37(2):260\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"833_CR79","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 2016;68(12):2901\u201310.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"833_CR80","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr2.11139","volume":"2","author":"AA Deodhar","year":"2020","unstructured":"Deodhar AA, Miceli-Richard C, Baraliakos X, et al. Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies. ACR Open Rheumatol. 2020;2(5):294\u20139.","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"833_CR81","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3899\/jrheum.201111","volume":"48","author":"G Schett","year":"2021","unstructured":"Schett G, Baraliakos X, Van den Bosch F, et al. Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies. J Rheumatol. 2021;48(8):1251\u20138.","journal-title":"J Rheumatol"},{"issue":"6","key":"833_CR82","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"833_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383\u201391.","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"833_CR84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11926-019-0819-8","volume":"21","author":"M Garrido-Cumbrera","year":"2019","unstructured":"Garrido-Cumbrera M, Poddubnyy D, Gossec L, et al. The European map of axial spondyloarthritis: capturing the patient perspective\u2014an analysis of 2846 patients across 13 countries. Curr Rheumatol Rep. 2019;21(5):19.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"833_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5114\/reum\/185429","volume":"62","author":"K Wi\u0105k-Walerowicz","year":"2024","unstructured":"Wi\u0105k-Walerowicz K, Wielosz E. Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity. Reumatologia. 2024;62(1):64\u20139.","journal-title":"Reumatologia"},{"key":"833_CR86","doi-asserted-by":"crossref","unstructured":"Marzo-Ortega H, Miceli-Richard C, Gill S, et al., editors. Subcutaneous secukinumab 150\u00a0mg provides sustained relief in total and nocturnal back pain, morning stiffness, fatigue, and low disease activity in patients with active ankylosing spondylitis: end-of-study (5-year) data from the MEASURE 2 trial. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 0364. https:\/\/acrabstracts.org\/abstract\/subcutaneous-secukinumab-150-mg-provides-sustained-relief-in-total-and-nocturnal-back-pain-morning-stiffness-fatigue-and-low-disease-activity-in-patients-with-active-ankylosing-spondylitis-end-of\/.","DOI":"10.1093\/rheumatology\/keaa111.241"},{"key":"833_CR87","unstructured":"Marzo-Ortega H, Deodhar A, Blanco R, et al., editors. Secukinumab improves pain, morning stiffness, fatigue and physical function in tumor necrosis factor inhibitor-na\u00efve patients with non-radiographic axial spondyloarthritis: results from a randomized controlled phase III study. Arthritis Rheumatol. 2020;72(suppl 10). Abstract 1340. https:\/\/acrabstracts.org\/abstract\/secukinumab-improves-pain-morning-stiffness-fatigue-and-physical-function-in-tumor-necrosis-factor-inhibitor-naive-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-c\/."},{"issue":"3","key":"833_CR88","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/ket397","volume":"53","author":"KL Haywood","year":"2014","unstructured":"Haywood KL, Packham JC, Jordan KP. Assessing fatigue in ankylosing spondylitis: the importance of frequency and severity. Rheumatology (Oxf). 2014;53(3):552\u20136.","journal-title":"Rheumatology (Oxf)"},{"issue":"4","key":"833_CR89","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/rheumatology\/keae549","volume":"64","author":"C Delcourt","year":"2025","unstructured":"Delcourt C, Fakih O, Prati C, Chouk M, Wendling D, Verhoeven F. Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxf). 2025;64(4):1585\u201397.","journal-title":"Rheumatology (Oxf)"},{"issue":"Suppl 11","key":"833_CR90","first-page":"S47","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S47\u201358.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"833_CR91","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","volume":"2","author":"H Marzo-Ortega","year":"2020","unstructured":"Marzo-Ortega H, Sieper J, Kivitz AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):e339\u201346.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"833_CR92","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"3","key":"833_CR93","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/RHU.0000000000002159","volume":"31","author":"M Jasmen","year":"2025","unstructured":"Jasmen M, Garc\u00eda D, Ib\u00e1\u00f1ez S, D\u00edaz P. The persistence of biologic therapies for psoriatic arthritis: a narrative review. J Clin Rheumatol. 2025;31(3):107\u201316.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"833_CR94","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","volume":"9","author":"MJ Moreno-Ramos","year":"2022","unstructured":"Moreno-Ramos MJ, Sanchez-Piedra C, Mart\u00ednez-Gonz\u00e1lez O, et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER registry. Rheumatol Ther. 2022;9(4):1031\u201347.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"833_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105824","volume":"92","author":"M Pons","year":"2025","unstructured":"Pons M, Georgiadis S, \u00d8stergaard M, et al. Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine. 2025;92(3):105824.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"833_CR96","doi-asserted-by":"publisher","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7(1):e001519.","journal-title":"RMD Open"},{"key":"833_CR97","unstructured":"Kiltz U, Sfikakis P, Bounas A, et al. Secukinumab retention and effectiveness in patients with psoriatic arthritis and radiographic axial spondyloarthritis: 5-year final results of a prospective real-world study [abstract]. Arthritis Rheumatol. 2024;76(suppl 9). Abstract 2344. https:\/\/acrabstracts.org\/abstract\/secukinumab-retention-and-effectiveness-in-patients-with-psoriatic-arthritis-and-radiographic-axial-spondyloarthritis-5-year-final-results-of-a-prospective-real-world-study\/."},{"issue":"3","key":"833_CR98","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76(3):571\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"833_CR99","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","volume":"5","author":"L Eder","year":"2023","unstructured":"Eder L, Mylvaganam S, Pardo Pardo J, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2023;5(12):e716\u201327.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"833_CR100","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/acr.25358","volume":"76","author":"P Mease","year":"2024","unstructured":"Mease P, Reed G, Ogdie A, Pappas DA, Kremer JM. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: association with disease severity assessment in a large US registry. Arthritis Care Res (Hoboken). 2024;76(9):1313\u201321.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"833_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003157","volume":"9","author":"YY Leung","year":"2023","unstructured":"Leung YY, Eder L, Orbai AM, et al. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study. RMD Open. 2023;9(3):e003157.","journal-title":"RMD Open"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00833-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:02:08Z","timestamp":1779530528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00833-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00833-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gurjit S. Kaeley has received research grants from AbbVie, Bristol Myers Squibb, Galapagos, Olatec, Novartis, and Jannsen. Alan Kivitz has received consulting fees from Horizon, Fresenius Kabi, Pfizer, GSK, Janssen, Selecta, Genzyme, Gilead, SynAct, Takeda, UCB, and Gr\u00fcnenthal; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, Eli Lilly, Pfizer, AbbVie, Amgen, and UCB; has been part of a board or advisory board for Horizon, Janssen, ChemoCentryx, UCB, and Novartis; and has stock or stock options in Pfizer, GSK, Gilead, Novartis, and Amgen. Philip Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Merck, MoonLake Pharma, Novartis, Pfizer, Takeda, and UCB; has received consulting fees from AbbVie, Bristol Myers Squibb, Century, Cullinan, Johnson & Johnson, Eli Lilly, Merck, MoonLake Pharma, Novartis, Oruka, Pfizer, Spyre, SUN Pharma, Takeda, and UCB; and has received speakers bureau fees from AbbVie, Amgen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and UCB. Pamela F. Weiss has received consulting fees from Pfizer and has been part of an advisory board for Pfizer and Bristol Myers Squibb. Linda Grinnell-Merrick is an employee of and owns stock in Novartis. Dafna D.\u00a0Gladman has received research grant support from AbbVie, Amgen, Eli Lilly, Fresenius Kabi, Novartis, Pfizer, and UCB and has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}